The Management Board of the European Medicines Agency (EMA) has
introduced a range of new measures to strengthen and extend its
conflicts of interest (COI) policy for scientific-committee members and
experts, as well as for members of the management board.
Taking into account the last 6 months’ experience, the EMA's policy
include measures to clarify involvement in academic trials and
publically funded R&D initiatives, as well as to align risk and
related restrictions for the different roles in the scientific decision
process and to tighten rules on grants from the pharmaceutical industry.
The new policy also outlines specific restrictions for board members,
such as preventing members from participating in discussions and
decision making.
Additional measures to support quality assurance were also agreed upon,
including the introduction of a breach of trust procedure for incomplete
or incorrect declarations of interest and retrospective cross-checking
of COI declarations and risk-mitigation measures.
http://www.pharmtech.com/pharmtech/News/EMA-Gets-Tough-on-Conflicts-of-Interest/ArticleStandard/Article/detail/767493?contextCategoryId=35097&ref=25
No comments:
Post a Comment